Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

Core Insights - Profusa, Inc. has decided not to proceed with a $15 million public offering, as it reassessed its near-term capital needs based on updated revenue projections for 2026 and its collaboration with Mayo Clinic [1][2] - The company plans to pursue a smaller, more focused offering to support projected revenue from its Lumee Oxygen product in Europe starting in Q2 2026 and to invest in its collaboration with Mayo Clinic for U.S. market entry [1][2] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, CA, focused on developing tissue-integrated sensors that provide continuous, actionable medical data [4] - The company aims to deliver long-lasting, injectable biosensors and an intelligent data platform to create personalized biochemical signatures for clinical use [4]